Verve Therapeutics Inc (VERV)
6.395
+0.36
(+5.88%)
USD |
NASDAQ |
Nov 05, 14:54
Verve Therapeutics Enterprise Value: -64.82M for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | -64.82M |
| November 01, 2024 | -74.12M |
| October 31, 2024 | -91.05M |
| October 30, 2024 | -85.97M |
| October 29, 2024 | -69.05M |
| October 28, 2024 | -73.28M |
| October 25, 2024 | -70.74M |
| October 24, 2024 | -91.90M |
| October 23, 2024 | -107.13M |
| October 22, 2024 | -94.43M |
| October 21, 2024 | -106.28M |
| October 18, 2024 | -97.82M |
| October 17, 2024 | -113.90M |
| October 16, 2024 | -102.05M |
| October 15, 2024 | -102.90M |
| October 14, 2024 | -150.29M |
| October 11, 2024 | -180.75M |
| October 10, 2024 | -186.68M |
| October 09, 2024 | -189.21M |
| October 08, 2024 | -193.45M |
| October 07, 2024 | -170.60M |
| October 04, 2024 | -152.83M |
| October 03, 2024 | -176.52M |
| October 02, 2024 | -169.75M |
| October 01, 2024 | -170.60M |
| Date | Value |
|---|---|
| September 30, 2024 | -166.37M |
| September 27, 2024 | -154.52M |
| September 26, 2024 | -156.21M |
| September 25, 2024 | -172.29M |
| September 24, 2024 | -157.06M |
| September 23, 2024 | -151.13M |
| September 20, 2024 | -136.75M |
| September 19, 2024 | -120.67M |
| September 18, 2024 | -109.67M |
| September 17, 2024 | -119.82M |
| September 16, 2024 | -117.28M |
| September 13, 2024 | -110.51M |
| September 12, 2024 | -97.82M |
| September 11, 2024 | -79.20M |
| September 10, 2024 | -101.20M |
| September 09, 2024 | -100.36M |
| September 06, 2024 | -102.47M |
| September 05, 2024 | -107.97M |
| September 04, 2024 | -59.74M |
| September 03, 2024 | -61.43M |
| August 30, 2024 | -8.964M |
| August 29, 2024 | -57.20M |
| August 28, 2024 | -79.20M |
| August 27, 2024 | -108.82M |
| August 26, 2024 | -143.52M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-206.69M
Minimum
Jun 27 2024
3.133B
Maximum
Sep 10 2021
796.40M
Average
611.90M
Median
Jan 03 2023
Enterprise Value Benchmarks
| Ardelyx Inc | 1.305B |
| Biomarin Pharmaceutical Inc | 12.24B |
| Sage Therapeutics Inc | -213.74M |
| ALX Oncology Holdings Inc | -68.47M |
| Immuneering Corp | -4.573M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -49.80M |
| Revenue (Quarterly) | 6.692M |
| Total Expenses (Quarterly) | 65.53M |
| EPS Diluted (Quarterly) | -0.59 |
| Profit Margin (Quarterly) | -744.2% |
| Earnings Yield | -40.50% |
| Normalized Earnings Yield | -40.50 |